Spero Therapeutics Income Statement (2016-2026) | SPRO

Income Statement Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
2.11M0.71M15.44M2.07M1.99M2.01M16.77M0.22M2.72M0.22M65.54M9.27M5.90M0.07M30.26M5.87M14.19M5.44M-7.35M0.26M
Operating items
Research & Development (Quarter)
14.46M14.44M17.23M16.97M8.17M7.36M15.09M8.98M9.51M16.39M16.56M17.33M23.73M26.86M28.84M13.61M10.67M8.60M5.59M2.91M
Selling, General & Administrative (Quarter)
9.23M11.15M13.02M15.30M8.05M6.63M6.50M7.32M6.10M5.71M6.43M5.92M5.53M5.20M7.06M6.82M5.88M4.17M4.30M4.89M
Restructuring Costs (Quarter)
11.85M-0.15M-8.62M0.88M0.17M0.08M
Other Operating Expenses (Quarter)
8.55M5.31M0.59M
Operating Expenses (Quarter)
23.69M25.59M30.25M32.28M28.07M13.84M21.52M16.30M15.61M27.41M22.99M23.25M29.26M32.06M36.77M20.61M16.63M13.36M9.89M7.80M
Operating Income (Quarter)
-18.54M-22.52M-27.50M-30.21M-26.08M-11.68M26.77M-14.23M-12.89M-1.93M54.45M-13.98M-19.06M-18.59M-25.39M-14.73M-2.44M-7.92M31.41M-7.54M
EBIT (Quarter)
-18.54M-22.52M-27.50M-30.21M-26.08M-11.68M26.77M-14.23M-12.89M-1.93M54.45M-13.98M-19.06M-18.59M-25.39M-14.73M-2.44M-7.92M31.41M-7.54M
Non-operating items
Interest & Investment Income (Quarter)
0.08M0.09M0.08M0.07M0.11M0.21M0.71M0.96M0.98M0.95M1.04M1.33M1.20M1.18M1.03M0.86M0.74M0.53M0.38M0.34M
Other Non Operating Income (Quarter)
0.20M-0.19M0.99M-0.02M0.14M-0.00M-0.01M-0.01M0.00M-0.01M0.00M-0.03M0.10M0.00M0.00M0.00M-0.00M
Non Operating Income (Quarter)
-0.03M0.00M-0.08M-0.01M-2.60M0.16M-0.01M-0.00M0.98M-0.01M1.05M-0.01M1.20M-0.03M-3.61M0.86M0.74M0.53M-2.14M-0.00M
Net income details
EBT (Quarter)
-18.46M-22.43M-27.43M-30.14M-25.97M-11.47M27.49M-13.26M-11.91M-0.98M55.50M-12.65M-17.86M-17.41M-24.36M-13.87M-1.70M-7.38M31.78M-7.20M
Tax Provisions (Quarter)
2.21M0.39M0.29M-0.29M0.26M
Profit After Tax (Quarter)
-18.57M-22.52M-29.28M-32.83M-28.68M-11.68M26.77M-13.27M-11.91M-3.20M51.21M-12.67M-17.86M-17.10M-20.90M-13.87M-1.70M-7.38M31.47M-7.20M
Income from Non-Controlling Interests (Quarter)
Income from Continuing Operations (Quarter)
-18.46M-22.43M-27.43M-30.14M-25.97M-11.47M27.49M-13.26M-11.91M-3.19M55.11M-12.65M-17.86M-17.70M-24.07M-13.87M-1.70M-7.38M31.52M-7.20M
Consolidated Net Income (Quarter)
-18.46M-22.43M-27.43M-30.14M-25.97M-11.47M27.49M-13.26M-11.91M-3.19M55.11M-12.65M-17.86M-17.70M-24.07M-13.87M-1.70M-7.38M31.52M-7.20M
Income towards Parent Company (Quarter)
-18.46M-22.43M-27.43M-30.14M-25.97M-11.47M27.49M-13.26M-11.91M-3.19M55.11M-12.65M-17.86M-17.70M-24.07M-13.87M-1.70M-7.38M31.52M-7.20M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)
-18.46M-22.43M-27.43M-30.14M-25.97M-11.47M27.49M-13.26M-11.91M-3.19M55.11M-12.65M-17.86M-17.70M-24.07M-13.87M-1.70M-7.38M31.52M-7.20M
Additional items
EPS (Basic) (Quarter)
-0.63-0.70-0.92-1.01-0.87-0.330.93-0.25-0.23-0.060.97-0.24-0.33-0.32-0.38-0.25-0.03-0.130.56-0.13
EPS (Weighted Average and Diluted) (Quarter)
-0.63-0.70-0.92-1.01-0.87-0.330.93-0.25-0.23-0.060.97-0.24-0.33-0.32-0.38-0.25-0.03-0.130.56-0.13
Shares Outstanding (Weighted Average) (Quarter)
29.68M32.13M30.90M32.61M32.79M33.83M37.59M52.53M52.57M52.60M52.70M53.52M53.74M53.87M54.04M55.38M56.03M56.28M56.02M57.28M
Shares Outstanding (Diluted Average) (Quarter)
29.55M30.42M30.90M32.61M32.79M33.83M37.59M52.53M52.57M52.71M52.99M53.52M53.96M54.12M54.04M55.38M55.70M55.87M59.04M57.28M
EBITDA (Quarter)
-18.57M22.52M-29.24M-32.83M-28.68M-11.68M26.77M-13.27M-11.91M-3.21M51.19M-13.98M-19.06M-18.59M-25.39M-14.73M-2.44M-7.92M31.41M-7.54M
Tax Rate (Quarter)
-224.70%0.70%-1.67%1.19%0.82%